Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial - 29/09/20
, Belinda Kingston, MB a, Lucy S Kilburn, MSc b, Sarah Kernaghan, BSc b, Andrew M Wardley, ProfMD e, f, Iain R Macpherson, MD g, Richard D Baird, MD h, Rebecca Roylance, MD i, j, Peter Stephens, PhD k, Olga Oikonomidou, MD l, Jeremy P Braybrooke, FRCP m, Mark Tuthill, MRCP n, Jacinta Abraham, BMBS o, Matthew C Winter, MD p, Hannah Bye, PhD q, Michael Hubank, PhD c, q, Heidrun Gevensleben, MD r, Ros Cutts, PhD a, Claire Snowdon, MSc b, Daniel Rea, ProfFRCP s, David Cameron, ProfMD l, Abeer Shaaban, PhD s, Katrina Randle, MSc t, Sue Martin, BSc b, Katie Wilkinson, BSc b, Laura Moretti, MSc b, Judith M Bliss, ProfMSc b, †, Alistair Ring, MD d, †Summary |
Background |
Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and the ability of ctDNA testing to select patients for mutation-directed therapy.
Methods |
We did an open-label, multicohort, phase 2a, platform trial of ctDNA testing in 18 UK hospitals. Participants were women (aged ≥18 years) with histologically confirmed advanced breast cancer and an Eastern Cooperative Oncology Group performance status 0–2. Patients had completed at least one previous line of treatment for advanced breast cancer or relapsed within 12 months of neoadjuvant or adjuvant chemotherapy. Patients were recruited into four parallel treatment cohorts matched to mutations identified in ctDNA: cohort A comprised patients with ESR1 mutations (treated with intramuscular extended-dose fulvestrant 500 mg); cohort B comprised patients with HER2 mutations (treated with oral neratinib 240 mg, and if oestrogen receptor-positive with intramuscular standard-dose fulvestrant); cohort C comprised patients with AKT1 mutations and oestrogen receptor-positive cancer (treated with oral capivasertib 400 mg plus intramuscular standard-dose fulvestrant); and cohort D comprised patients with AKT1 mutations and oestrogen receptor-negative cancer or PTEN mutation (treated with oral capivasertib 480 mg). Each cohort had a primary endpoint of confirmed objective response rate. For cohort A, 13 or more responses among 78 evaluable patients were required to infer activity and three or more among 16 were required for cohorts B, C, and D. Recruitment to all cohorts is complete and long-term follow-up is ongoing. This trial is registered with ClinicalTrials.gov, NCT03182634; the European Clinical Trials database, EudraCT2015-003735-36; and the ISRCTN registry, ISRCTN16945804.
Findings |
Between Dec 21, 2016, and April 26, 2019, 1051 patients registered for the study, with ctDNA results available for 1034 patients. Agreement between ctDNA digital PCR and targeted sequencing was 96–99% (n=800, kappa 0·89–0·93). Sensitivity of digital PCR ctDNA testing for mutations identified in tissue sequencing was 93% (95% CI 83–98) overall and 98% (87–100) with contemporaneous biopsies. In all cohorts, combined median follow-up was 14·4 months (IQR 7·0–23·7). Cohorts B and C met or exceeded the target number of responses, with five (25% [95% CI 9–49]) of 20 patients in cohort B and four (22% [6–48]) of 18 patients in cohort C having a response. Cohorts A and D did not reach the target number of responses, with six (8% [95% CI 3–17]) of 74 in cohort A and two (11% [1–33]) of 19 patients in cohort D having a response. The most common grade 3–4 adverse events were raised gamma-glutamyltransferase (13 [16%] of 80 patients; cohort A); diarrhoea (four [25%] of 20; cohort B); fatigue (four [22%] of 18; cohort C); and rash (five [26%] of 19; cohort D). 17 serious adverse reactions occurred in 11 patients, and there was one treatment-related death caused by grade 4 dyspnoea (in cohort C).
Interpretation |
ctDNA testing offers accurate, rapid genotyping that enables the selection of mutation-directed therapies for patients with breast cancer, with sufficient clinical validity for adoption into routine clinical practice. Our results demonstrate clinically relevant activity of targeted therapies against rare HER2 and AKT1 mutations, confirming these mutations could be targetable for breast cancer treatment.
Funding |
Cancer Research UK, AstraZeneca, and Puma Biotechnology.
Le texte complet de cet article est disponible en PDF.Plan
Vol 21 - N° 10
P. 1296-1308 - octobre 2020 Retour au numéro
Article précédent
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
- Leisha A Emens, Francisco J Esteva, Mark Beresford, Cristina Saura, Michelino De Laurentiis, Sung-Bae Kim, Seock-Ah Im, Yifan Wang, Roberto Salgado, Aruna Mani, Jigna Shah, Chiara Lambertini, Haiying Liu, Sanne L de Haas, Monika Patre, Sherene Loi
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
- Lennard Y W Lee, Jean-Baptiste Cazier, Thomas Starkey, Sarah E W Briggs, Roland Arnold, Vartika Bisht, Stephen Booth, Naomi A Campton, Vinton W T Cheng, Graham Collins, Helen M Curley, Philip Earwaker, Matthew W Fittall, Spyridon Gennatas, Anshita Goel, Simon Hartley, Daniel J Hughes, David Kerr, Alvin J X Lee, Rebecca J Lee, Siow Ming Lee, Hayley Mckenzie, Chris P Middleton, Nirupa Murugaesu, Tom Newsom-Davis, Anna C Olsson-Brown, Claire Palles, Thomas Powles, Emily A Protheroe, Karin Purshouse, Archana Sharma-Oates, Shivan Sivakumar, Ashley J Smith, Oliver Topping, Chris D Turnbull, Csilla Várnai, Adam D M Briggs, Gary Middleton, Rachel Kerr, UK Coronavirus Cancer Monitoring Project Team, Abigail Gault, Michael Agnieszka, Ahmed Bedair, Aisha Ghaus, Akinfemi Akingboye, Alec Maynard, Alexander Pawsey, Ali Abdulnabi Suwaidan, Alicia Okines, Alison Massey, Amy Kwan, Ana Ferreira, Angelos Angelakas, Anjui Wu, Ann Tivey, Anne Armstrong, Annet Madhan, Annet Pillai, Ashley Poon-King, Bartlomiej Kurec, Caroline Usborne, Caroline Dobeson, Christina Thirlwell, Christian Mitchell, Christopher Sng, Christopher Scrase, Christopher Jingree, Clair Brunner, Claire Fuller, Clare Griffin, Craig Barrington, Daniel Muller, Diego Ottaviani, Duncan Gilbert, Eliana Tacconi, Ellen Copson, Emily Renninson, Emma Cattell, Emma Burke, Fiona Smith, Francesca Holt, Gehan Soosaipillai, Hayley Boyce, Heather Shaw, Helen Hollis, Helen Bowyer, Iris Anil, Jack Illingworth, Jack Gibson, Jaishree Bhosle, James Best, Jane Barrett, Jillian Noble, Joseph Sacco, Joseph Chacko, Julia Chackathayil, Kathryn Banfill, Laura Feeney, Laura Horsley, Lauren Cammaert, Leena Mukherjee, Leonie Eastlake, Louise Devereaux, Lucinda Melcher, Lucy Cook, Mabel Teng, Madeleine Hewish, Madhumita Bhattacharyya, Mahbuba Choudhury, Mark Baxter, Martin Scott-Brown, Matthew Fittall, Michael Tilby, Michael Rowe, Michael Agnieszka, Mohammed Alihilali, Myria Galazi, Nadia Yousaf, Neha Chopra, Nicola Cox, Olivia Chan, Omar Sheikh, Paul Ramage, Paul Greaves, Pauline Leonard, Peter S Hall, Piangfan Naksukpaiboon, Pippa Corrie, Rahul Peck, Rachel Sharkey, Rachel Bolton, Rebecca Sargent, Rema Jyothirmayi, Robert Goldstein, Roderick Oakes, Rohan Shotton, Ruhi Kanani, Ruth Board, Ruth Pettengell, Ryan Claydon, Sam Moody, Samah Massalha, Sangary Kathirgamakarthigeyan, Saoirse Dolly, Sarah Derby, Sarah Lowndes, Sarah Benafif, Sarah Eeckelaers, Sarah Kingdon, Sarah Ayers, Sean Brown, Shawn Ellis, Shefali Parikh, Sian Pugh, Simon Shamas, Simon Wyatt, Simon Grumett, Sin Lau, Yien Ning Sophia Wong, Sophie McGrath, Stephanie Cornthwaite, Stephen Hibbs, Tania Tillet, Taslima Rabbi, Tim Robinson, Tom Roques, Vasileios Angelis, Victoria Woodcock, Victoria Brown, YingYing Peng, Yvette Drew, Zoe Hudson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?